OncoMatch/Clinical Trials/NCT06457906

SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC

Is NCT06457906 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Experimental group (SRS/SRT/Hypo-RT) for small-cell lung cancer.

Phase 3RecruitingCancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06457906Data as of May 2026

Treatment: Experimental group (SRS/SRT/Hypo-RT) — This phase III trial compares the effect of stereotactic radiosurgery and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Disease stage

Metastatic disease required

Performance status

ECOG OR KARNOFSKY 0–2

Prior therapy

Cannot have received: radiation therapy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify